Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
Real-time Euronext Paris  -  11:39:57 2023-02-03 am EST
85.14 EUR   -1.88%
02/03Health Care Edge Lower After Solid Earnings -- Health Care Roundup
DJ
02/03SANOFI : Goldman Sachs reiterates its Buy rating
MD
02/03French Bourse Close Higher Friday as Private Sector Activity Remains Stable
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sanofi Says Any Potential Offer for Horizon Therapeutics Will Be Made in Cash

12/02/2022 | 05:28am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
AMGEN INC. -0.55% 245.17 Delayed Quote.-6.13%
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY -0.10% 109.68 Delayed Quote.-3.52%
JOHNSON & JOHNSON -0.56% 164.61 Delayed Quote.-6.29%
SANOFI -1.88% 85.14 Real-time Quote.-5.23%
All news about SANOFI
02/03Health Care Edge Lower After Solid Earnings -- Health Care Roundup
DJ
02/03SANOFI : Goldman Sachs reiterates its Buy rating
MD
02/03French Bourse Close Higher Friday as Private Sector Activity Remains Stable
MT
02/03Sanofi CEO Says UK Regulations Impeding Pharmaceutical Industry Success
MT
02/03Regeneron Pharmaceuticals' Revenue Slides, Still Tops Street Views as R&D Spending Pick..
MT
02/03Transcript : Sanofi, Q4 2022 Earnings Call, Feb 03, 2023
CI
02/03Tech Earnings Assessed as Exchange-Traded Funds, Equity Futures Fall Premarket Friday
MT
02/03Futures Slide Pre-Bell Over Mixed Tech Earnings; Asia Gains, Europe Wobbles
MT
02/03Sanofi forecasts profit growth amid competition
RE
02/03French Stocks Drop at Midday After ECB Outlook Confuses Market, Business Activity Contr..
MT
More news
Analyst Recommendations on SANOFI
More recommendations
Financials
Sales 2022 43 479 M 47 183 M 47 183 M
Net income 2022 7 446 M 8 080 M 8 080 M
Net Debt 2022 7 219 M 7 834 M 7 834 M
P/E ratio 2022 14,5x
Yield 2022 4,17%
Capitalization 106 B 115 B 115 B
EV / Sales 2022 2,61x
EV / Sales 2023 2,40x
Nbr of Employees 95 442
Free-Float 88,0%
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 85,14 €
Average target price 105,18 €
Spread / Average Target 23,5%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Director
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI-5.23%115 251
JOHNSON & JOHNSON-6.29%430 370
ELI LILLY AND COMPANY-9.61%322 186
NOVO NORDISK A/S0.37%309 572
ROCHE HOLDING AG-2.81%269 030
MERCK & CO., INC.-7.22%260 994